While the condition does not require treatment nor pose a significantly increased risk of drug toxicity, patients with a combination of UGT1A SNPs are more likely to develop hyperbilirubinemia during treatment with atazanavir [44]. Here, UGT1A1 is linked to Hyperbilirubinemia.